Activist Investor Pushes for Avantor Board Revamp Amid Declining Shares

Activist investor Engine Capital is calling for significant changes at Avantor, a leading supplier in the life sciences sector. With a 3% stake in the company, Engine Capital has suggested a board refresh, cost-cutting measures, and the exploration of a potential sale. These recommendations come in the wake of Avantor’s stock plummeting 45% this year, largely due to weakened demand and industry funding cuts. The company’s shares soared nearly 8% following the announcement, reflecting investor interest in a strategic pivot.

Avantor, renowned for providing critical chemicals, lab products, and services to the research and biopharma sectors, has witnessed considerable challenges over the past five years. Citing repeated forecast downgrades and performance gaps, Engine Capital criticized the board’s oversight on management and strategic planning. Given the broader industry trend towards consolidation, Engine Capital believes merging with a larger entity could benefit Avantor, potentially driving its shares up to $26 by 2027. In response, Avantor reaffirmed its commitment to executing strategies in the best interests of its shareholders and expressed willingness for ongoing dialogue.